Introduction
============

Cancer is one of the leading causes of morbidity and mortality worldwide, with approximately 14 million new cases per year according to the World Cancer Report 2014[@B1]. Exposure to carcinogens and harmful metabolites is one of etiologic factors for urinary system cancer[@B2], [@B3]. Cytosolic glutathione S-transferases (GSTs) are members of a phase II metabolic isozymes super family, which protect cells against electrophilic damage by catalyzing the conjugation between carcinogens and glutathione. This catalytic reaction decreases the toxicity of carcinogens and facilitates their excretion from the body. Additionally, certain GSTs also protect tissues against injury by attenuating oxidative stress or modulating the signaling pathways of cell proliferation, apoptosis and differentiation[@B4], [@B5]. The *glutathione S-transferase theta 1* (*GSTT1*) is located on the long arm of chromosome 22 (22q11.23)[@B6]. Some studies reported that GSTT1 protein was involved in catalyzing the conjugation of ethylene oxide and halogenated metabolites[@B7]. Moreover, GSTT1 is also involved in the activation of p38/MAPKAP kinase 2(MK2) signal pathway. GSTT1 may prevent cells from tumorigenesis via promoting p38/MK2-mediated apoptosis and senescence. High thiol levels and the absence of oxidative stress keep the GSTT1 in monomeric form. In the presence of pro-oxidative stimuli, dimerized GSTT1 bind to p38 and MK2 to facilitate the activation of these kinases, which in turn elevate the expression of *GSTT1*. After interacting with MKK3, Phosphorylated p38 and MK2 reduce the polarization of mitochondrial membrane potential, which activates apoptosis and senescence[@B8] (as shown in **Fig [1](#F1){ref-type="fig"}**). Dysfunction of GSTs has been implicated in the development of bladder cancer, prostate cancer, or renal cell carcinoma, due to the defective detoxification capacity [@B9], [@B10]. The *GSTT1* polymorphism (*GSTT1*presence and *GSTT1* null) has been proved in several studies to be associated with an increased risk of urinary system cancer[@B11]-[@B13]. However, the results from different groups were to some extent divergent[@B14], [@B15], which might be owing to the limitations of individual studies, including the heterogeneity in the sample source, study design or disagreements among the investigations. A comprehensive meta-analysis might provide sufficient statistical power to draw a more reliable conclusion on the association between *GSTT1* null genotype and urinary system cancer risk. Therefore, we conducted the current meta-analysis using genotype data from 117 eligible studies to assess such association.

Materials and Methods
=====================

The strategy of literature screening, data collection, and studies inclusion in this meta-analysis was according to the latest meta-analysis guidelines-Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)[@B16].

Search Strategy
---------------

A systematic literature retrieval was performed using the following key words: \"glutathione S-transferase T1 or *GSTT1*\", \"variant or variation or polymorphism " and "bladder or prostate or renal cell carcinoma or urinary system cancer" through PubMed and EMBASE databases without any restriction on language (the last search update was performed on Nov 24, 2015). We further searched articles from Chinese Biomedical (CBM) and China National Knowledge Infrastructure (CNKI) databases to ensure more studies were include in this research. We also searched the references of the relevant literatures manually. All the eligible studies were listed in the reference.

Inclusion Criteria
------------------

The inclusion criteria were as follows: (a) evaluated the association between *GSTT1*null genotype and urinary system cancer susceptibility; (b) only case-control studies were taken into account; (c) with details for calculating odds ratios (ORs) and corresponding 95% confidence intervals (CIs); (d) presented in English or Chinese. If the study had overlapping subjects with others, only the most complete and latest one was included.

The exclusion criteria were: (a) case only studies; (b)case reports; (c) conference abstracts; review articles; (d) non-cancer subjects only studies; (e)duplicate publications.

Data Extraction
---------------

Two of the authors (Y.W. and J.H.) independently extracted the information from all the eligible studies. While there was a disagreement between them, they made a discussion about the issue. If they could not reach a consensus, another author would participate to resolve the dispute, and authors would vote to make a final decision. Data extracted from each study were as follows: the surname of first author, year of publication, country and ethnicity of the subjects, case number and control number with the *GSTT1* null, number of total subjects, source of control, genotyping method, and case confirmation approach. The types of cancer were consist of bladder cancer, prostate cancer and renal cell carcinoma. Ethnicities were categorized into Africans, Asians, Caucasians, Indians and Mixed (containing more than one ethnic group). The sources of control were classified as population-based(PB) and hospital-based(HB). The minimum number of patients was not defined for inclusion in this meta-analysis. Publications were divided into different categories by the type of cancer, ethnicity, source of control or quality score.

Quality Score Assessment
------------------------

The quality of the study was independently assessed by two investigators (Y.W. and J.H.) via the quality assessment criteria (**Table [S1](#SM1){ref-type="supplementary-material"}**)[@B17],[@B18]. The evaluation factors were as follows: representativeness of case, representativeness of control, ascertainment of urinary system cancer, control selection, genotyping examination, and total sample size. Each research was evaluated on a scale from 0-15. If the score of one study was ≤5, it was classified as \"low quality\"; 5\<scores≤10, \"medium quality\"; scores\>10, it was categorized as \"high quality\".

Statistical Methods
-------------------

Crude ORs and the corresponding 95% CIs were used to evaluate the strength of association between *GSTT1* null genotype and urinary system cancer susceptibility. The statistical significance of an association was determined by Z test. The between-studies heterogeneity was assessed and qualified using cochran Q-test and *I*^2^ statistic. For Q test, when *P*\<0.10, the heterogeneity was considered statistically significant. *I*^2^ statistic represented the proportion of variants caused by heterogeneity across studies but not sampling error. In this meta-analysis, if heterogeneity was *P*\>0.10 for Q-test, a fixed-effect model was applied; otherwise, a random-effect model was conducted. The leave-one-out sensitivity analysis was performed by excluding a study in the meta-analysis each time and recalculating ORs. Moreover, the publication bias was detected by Begg\'s and Egger\'s linear regression tests. The symmetry of the funnel plot suggested null publication bias; otherwise, the publication bias was present. Finally, a meta-regression was conducted to detect the main heterogeneity source among the studies included in our analysis.

All statistical analyses were performed using the meta software package of STATA version 12.0 (STATA Corporation, College Station, TX). All the*P* values were two-side tests. *P*\<0.05 was considered statistically significant.

Results
=======

Study characteristics
---------------------

A total of 189 relative articles were obtained from CBM, CNKI, EMBASE and PubMed using search terms according to the search strategy in methods section. After screening the title or abstract, 44 articles that were either not related to urinary system cancer or reviews were excluded. The remaining 145 publications were carefully evaluated according to the eligibility criteria. Among them, 31 articles were removed because they were duplicated studies (n=4), not case-control studies (n=6), useless in *GSTT1* genotyping data extraction (n=10) or meta-analysis (n=11). Therefore, 114 publications were subjected to further analysis. Among them, 3 additional studies were extracted from publications containing two studies[@B9], [@B17], [@B18]. For example, Steinhoff and his colleagues investigated the association of *GSTT1* null genotype with both bladder and prostate cancer risk[@B9]. Finally, 117 eligible case-control studies with 26,666 cases and 37,210 controls meeting the criteria were included in our analysis[@B9]-[@B15], [@B17]-[@B89] [@B90]-[@B123]. The flowchart of the identification of eligible studies was shown in **Fig [2](#F2){ref-type="fig"}**.

**Table [1](#T1){ref-type="table"}** summarized all the eligible studies and main characteristics. The sample size ranged from 46 to 4,537 in the 117 studies, including 60, 46 and 11 studies focusing on bladder cancer, prostate cancer, and renal cell carcinoma, respectively. According to the race, these studies could be classified into 5 subgroups, Africans(68 studies), Asians(20 studies) , Caucasians(5 studies), Indians(10 studies) and mixed populations(14 studies). The majority of the patients(94%) with urinary system cancer were histologically confirmed, and 6% of the patients were determined by the medical records. Controls were frequency-matched to patients by age, gender and ethnicity in most of studies. Of all the studies, 49 studies were PB, while 68 were HB. Additionally, 19 studies were considered as low quality(score≤5), 79 studies were considered as medium quality(5\<score≤10), and 19 studies were considered as high quality(score\>10).

Meta-analysis results
---------------------

The main results of the meta-analysis were shown in **Table [2](#T2){ref-type="table"}, Fig [3](#F3){ref-type="fig"}** and **Fig [4](#F4){ref-type="fig"}**. Pooled analysis yielded a significant association between *GSTT1* null genotype and urinary system risk (OR=1.13, 95%CI=1.05-1.22). In the stratification analysis by the type of cancer, significantly increased risk of bladder cancer and prostate cancer was observed with *GSTT1* null genotype (bladder cancer: OR=1.13, 95%CI=1.03-1.24; prostate cancer: OR=1.14, 95%CI=1.01-1.29). Subgroup analysis by ethnicity revealed a significantly increased urinary system cancer risk for Caucasians and Indians (Caucasians: OR=1.16, 95%CI=1.05-1.27; Indians: OR=2.05, 95%CI=1.700-2.480). By source of control, a statistically significant association was confirmed in PB subgroup (OR=1.15, 95%CI=1.04-1.27). Moreover, when 117 studies were stratified by quality score, the presence of *GSTT1* null genotype was associated with urinary system cancer risk in the low quality and medium quality subgroup (score≤5: OR=1.43, 95%CI=1.13-1.79; 5\<score≤10: OR=1.15, 95%CI=1.40-1.26).

Q test and*I^2^* statistic were applied to assess the heterogeneity between 117 studies. There were considerable heterogeneities for the *GSTT1* genotype and urinary system cancer risk in the overall analysis(*P*=0.000, *I*^2^=65.0%). Thereafter, we applied meta-regression to investigate the sources of heterogeneity by the type of cancer, ethnicity, source of control and quality score. As shown in **Table [3](#T3){ref-type="table"}**, we found the ethnicity and quality of the study contributing to the heterogeneity in this meta-analysis (ethnicity: *P*=0.003; quality score: *P*=0.002), but not the type of cancer and source of control (the type of cancer: *P*=0.703; source of control: *P*=0.175).

Sensitivity analysis
--------------------

To detect the effect of individual data-set on the stability of the pooled analysis, we performed the sensitivity analysis by consecutively excluding a study at a time and recalculating ORs. As a result, there was no substantial change in the corresponding pooled ORs, suggesting that our analysis was statistically stable(**Fig [5](#F5){ref-type="fig"}**) .

Publication bias
----------------

Begg\'s (**Fig [6](#F6){ref-type="fig"}**) test and Egger\'s test were conducted to assess the publications bias of 117 studies. The results indicated a statistically significant evidence of publication bias in the meta-analysis (*P*=0.002). Interestingly, when we dropped the low quality studies with score≤5, publication bias disappeared (*P*=0.052). The data suggested that the bias might be caused by those studies with poor genotyping method or selectively reported positive results.

Discussion
==========

This is a comprehensive meta-analysis for the relationship between the *GSTT1* null genotype and the urinary system cancer risk. There were 117 studies with a total of 26,666 cases and 37,210 controls included. Pooled analysis suggested that *GSTT1* null genotype was associated with a significantly increased risk of urinary system cancer. In the stratified analysis by the type of cancer , *GSTT1* null genotype was shown to significantly increase the risk of bladder cancer and prostate cancer, but not renal cell carcinoma. Moreover, while stratified analysis were conducted by ethnicity, source of control and quality score, significant association were identified among Caucasians and Indians, PB subgroup and high score subgroup. So far, this is the first meta-analysis to evaluate the association between *GSTT1* null genotype and urinary system cancer risk with the largest sample size of 63,876 subjects in this area.

The GST super family belongs to phase II detoxifying enzymes. They catalyze the reduction reactions between glutathione and electrophilic substrates, producing stable and harmless compounds. Then these compounds are excreted or compartmentalized[@B124]. *GSTT1* gene is located on the long arm of chromosome 22 (22q11.23) and composed of 5 exons[@B6]. Apart from the well-established roles in detoxification, each GST has specific function. For instance, GSTT1 is involved in p38/MK2 mediated senescence[@B8], and conjugation with small molecular-epoxides, which may attenuate the injury from inflammation to cancer progression[@B125]. There is a null variant allele of *GSTT1* gene, which results in an absence of GST enzyme activity and an increased risk to malignancies. Many studies were performed to evaluate the association between *GSTT1* null genotype and the susceptibility to urinary system cancer. However, the results from different laboratories were not consistent. Numerous reports suggested that there was an significant association between *GSTT1* null genotype and urinary system cancer[@B9]-[@B13], [@B20], [@B21], while several other studies failed to detect any association between renal cell carcinoma and *GSTT1* null variant[@B114], [@B117], [@B118]. Some meta-analysis were performed to evaluate the association between *GSTT1* null genotype and bladder cancer, prostate cancer or renal cell carcinoma, respectively, overall or in a certain population[@B126]-[@B129]. Our analysis included all the eligible studies regardless of the types of cancer like bladder cancer, prostate cancer or renal cell carcinoma. The results of the current meta-analysis confirmed a significant association between *GSTT1* null genotype and the susceptibility of urinary system cancer. However, this variant was proven to significantly increase the predisposition to bladder cancer and prostate cancer in stratified analysis by the type of cancer, but not renal cell carcinoma. SNPs in a gene were typically cancer-specific. The discrepancy might owe to the inherent heterogeneity of oncogenic progression in different cancer. The stratified analysis by ethnicity verified that *GSTT1* null variant significantly increased the urinary system cancer predisposition in Caucasian and Indian subgroups.

Moreover, a significant increased risk was indicated in PB subgroup, but not in HB subgroup. This was probably due to that the controls collected from hospital were not capable of representing the general population, which might decrease the risk value. Stratification analysis also showed the heterogeneities of between-studies in the overall analysis. We further conducted the meta-regression to assess the factors contributing to the strong heterogeneities among overall analysis. The results suggested that the ethnicity and quality of the study were the main factors associated with the heterogeneities. First, cancer is a complicated disease induced by the gene-environment interaction. People born in different geographic areas has different genetic background and life style. There are different linkage disequilibrium patterns in different populations. Supposed that *GSTT1* polymorphism is in close linkage with a causal mutation in Caucasians and Indians but not other ethnicity, the discrepancy can be explained. Besides, the effects from clinical features and live surroundings of different population should be well-contemplated. The second, studies with poor genotyping method and selectively reported positive results also contributed to the heterogeneities. Therefore, more studies are needed to investigate the heterogeneity in further research.

Compared to the former meta-analysis, the current one might possess the following merits: (a) This meta-analysis included the latest studies till Nov, 2015 to make it more comprehensive and minimize the selection bias; (b) The study drew a more complete conclusion about *GSTT1* null variant and urinary system cancer risk, but not only bladder cancer or prostate cancer; (c)This investigation conducted a systematical stratification and meta-regression analysis, which provided a more precise conclusion; (d)The sample size and study number were relatively larger, and the statistical power was more potent. However, there were some limitations in this meta-analysis which should be taken into consideration. First, the study number about renal cell carcinoma (n=11) or Africans (n=5) was small, compared to the studies about bladder cancer(n=60) or Caucasians(n=68). Because of the relatively small sample size, the stratified studies regarding renal cell carcinoma and Africans might have a lower statistical power to detect the substantial effects of *GSTT1* null genotype on the risk. Second, not all the studies provided enough data about lifestyles (example, smoking, drinking alcohol or tea) or environmental exposure which were reported to be important for the development of urinary system cancer. Third, the selection bias was exist. When we dropped the low quality studies with score≤5, publication bias was not present. There might be a language bias, inflated evaluations or selectively reported positive result in studies of low quality.

To summarize, this systematic meta-analysis regarding the relationship between *GSTT1* null genotype and urinary system cancer indicated that this variant significantly increased the risk of urinary system cancer. Moreover, the significant association was found in bladder cancer, prostate, Caucasians, Indians, PB subgroup, but not in renal cell carcinoma, Africans, Asians, Mixed and HB subgroup. The well-designed, large-cohort and multi-center studies are needed to present more rigorous data to confirm our findings.
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![**Schematic of the potential roles of *GSTT1* in preventing cells from tumorigenesis**. *GSTT1* prevent cells from tumorigenesis via promoting p38/MK2 mediated apoptosis and senescence. High thiol levels and the absence of oxidative stress keep the*GSTT1* in monomeric form. (A) Monomeric *GSTT1* dissociates from p38 and MK2, and binds to its inhibitor. (B) In the presence of pro-oxidative stimuli, dimerized *GSTT1* binds to p38 and MK2, promoting the activity of these kinases, which in turn elevate the expression of *GSTT1*. (C) After interacting with MKK3, Phosphorylated p38 and MK2 initiate the reduction of polarization of mitochondrial membrane potential, which activates apoptosis and senescence. Abbreviations: *GSTT1*, glutathione S‑transferase theta 1; MK2, mitogen-activated protein kinase-activated protein kinase 2; MKK3, mitogen-activated protein kinase 3.](jcav07p1680g001){#F1}

![Flowchart of included studies for the meta-analysis of the association between *GSTT1* null genotype and urinary system cancer risk.](jcav07p1680g002){#F2}

![**Forest plot of the association between *GSTT1* null genotype and urinary system cancer risk.** For each study, the estimates of ORs and corresponding 95% CI are plotted with a box and a horizontal line. Diamond, pooled ORs and its 95% CI.](jcav07p1680g003){#F3}

![**Forest plot of the association between *GSTT1* null genotype and urinary system cancer risk which is straitified by the type of cancer.**For each study, the estimates of ORs and corresponding 95% CI are plotted with a box and a horizontal line. Diamond, pooled ORs and its 95% CI.](jcav07p1680g004){#F4}

![**Sensitivity analysis of the association between *GSTT1* null genotype and urinary system cancer risk.**Each point represents the recalculated OR after deleting a separate study.](jcav07p1680g005){#F5}

![**Funnel plot analysis to detect the publication bias for *GSTT1* null genotype and urinary system cancer risk.**Each point represents a separate study. Funnel plot of the Begg\'s test for (A) 117 studies, *Z*=3.03, *P*=0.002; and (B) for 98 studies after dropping 19 studies with low quality, *Z*=1.94, *P*=0.052.](jcav07p1680g006){#F6}

###### 

Characteristics of the 117 studies included in the meta-analysis for the association between *GSTT1* null genotype and risk of urinary system cancer

  Surname               Year   Country      Ethnicity    Type of cancer         Sourceof control   Genotyping method               Cases   Controls   MAF(T)   Score
  --------------------- ------ ------------ ------------ ---------------------- ------------------ ------------------------------- ------- ---------- -------- -------
  Kempkes               1996   Germany      Caucasians   Bladder cancer         PB                 PCR                             113     170        0.18     6
  Bruning               1997   Germany      Caucasians   Renal cell caicinoma   PB                 PCR                             45      48         0.23     6
  Salagovic             1998   Slovak       Caucasians   Bladder cancer         PB                 PCR                             67      248        0.17     5
  Kim                   1998   Korea        Asians       Bladder cancer         HB                 PCR                             67      67         0.43     6
  Abdel-Rahman          1998   Egypt        Caucasians   Bladder cancer         PB                 PCR                             37      34         0.15     8
  Katoh                 1998   Japan        Asians       Bladder cancer         PB                 PCR                             112     112        0.47     9
  Salagovic             1999   Slovak       Caucasians   Bladder cancer         PB                 PCR                             76      248        0.17     5
  Autrup                1999   Denmark      Caucasians   Prostate cancer        PB                 PCR                             153     288        0.15     7
  Lee                   1999   Korea        Asians       Bladder cancer         HB                 PCR                             158     131        0.50     7
  Rebbeck               1999   USA          Mixed        Prostate cancer        PB                 PCR                             232     231        0.69     8
  Longuemaux            1999   France       Caucasians   Renal cell caicinoma   HB                 PCR                             173     211        0.19     8
  Schnakenberg          2000   Germany      Caucasians   Bladder cancer         PB                 PCR                             157     223        0.22     5
  Steinhoff             2000   Germany      Caucasians   Bladder cancer         HB                 PCR                             135     127        0.13     5
  Steinhoff             2000   Germany      Caucasians   Prostate cancer        HB                 PCR                             91      127        0.13     5
  Peluso                2000   Italy        Caucasians   Bladder cancer         HB                 PCR                             122     54         0.11     6
  Kim                   2000   Korea        Asians       Bladder cancer         HB                 PCR                             112     220        0.46     7
  Kelada                2000   USA          Mixed        Prostate cancer        HB                 PCR                             256     469        0.33     7
  Sweeney               2000   USA          Mixed        Renal cell caicinoma   PB                 PCR                             126     504        0.18     9
  Murata                2001   Japan        Asians       Prostate cancer        PB                 PCR                             115     200        0.48     6
  Toruner               2001   Turkey       Caucasians   Bladder cancer         HB                 PCR                             121     121        0.17     6
  Gsur                  2001   Austria      Caucasians   Prostate cancer        HB                 PCR                             166     166        0.20     8
  Kote-Jarai            2001   UK           Caucasians   Prostate cancer        PB                 PCR                             273     278        0.24     10
  Ma                    2002   China        Asians       Bladder cancer         PB                 PCR                             61      182        0.48     5
  Lee                   2002   Korea        Asians       Bladder cancer         HB                 PCR                             232     165        0.52     6
  Giannakopoulos        2002   Greece       Caucasians   Bladder cancer         HB                 PCR                             89      147        0.11     6
  Beer                  2002   USA          Caucasians   Prostate cancer        PB                 PCR                             111     146        0.23     7
  Kim                   2002   Korea        Asians       Bladder cancer         PB                 PCR                             216     449        0.51     10
  Jong Jeong            2003   Korea        Asians       Bladder cancer         HB                 PCR                             126     204        0.55     6
  Nakazato              2003   Japan        Asians       Prostate cancer        PB                 PCR                             81      105        0.42     7
  Buzio                 2003   Italy        Caucasians   Renal cell caicinoma   HB                 PCR                             100     200        0.18     8
  Kidd                  2003   Finland      Caucasians   Prostate cancer        PB                 PCR                             202     189        0.15     10
  Gago-Dominguez        2003   USA          Mixed        Bladder cancer         PB                 PCR                             196     176        0.19     10
  Srivastava            2004   India        Indians      Bladder cancer         HB                 PCR                             106     182        0.16     4
  Mittal                2004   India        Indians      Prostate cancer        PB                 PCR                             103     117        0.11     5
  Chen                  2004   China        Asians       Bladder cancer         PB                 PCR                             62      81         0.63     6
  Hung                  2004   Italy        Caucasians   Bladder cancer         HB                 PCR                             201     214        0.15     6
  Sanyal                2004   Sweden       Caucasians   Bladder cancer         PB                 PCR                             270     122        0.10     8
  Medeiros              2004   Portugal     Caucasians   Prostate cancer        PB                 PCR                             145     184        0.24     9
  Joseph                2004   USA          Caucasians   Prostate cancer        PB                 PCR-RFLP                        177     265        0.23     9
  Moore                 2004   Argentina    Caucasians   Bladder cancer         PB                 PCR                             106     109        0.11     10
  Wang                  2005   China        Asians       Prostate cancer        HB                 PCR                             81      90         0.53     3
  Sobti                 2005   India        Indians      Bladder cancer         PB                 PCR                             100     76         0.14     5
  Golka                 2005   Germany      Caucasians   Bladder cancer         HB                 PCR                             136     163        0.23     5
  Saad                  2005   Egypt        Caucasians   Bladder cancer         PB                 PCR                             72      81         0.17     6
  Komiya                2005   Japan        Asians       Prostate cancer        PB                 PCR                             186     288        0.52     8
  Srivastava            2005   India        Indians      Bladder cancer         PB                 PCR                             106     370        0.21     8
  Srivastava            2005   India        Indians      Prostate cancer        PB                 PCR                             127     144        0.20     8
  Kim                   2005   Korea        Asians       Bladder cancer         HB                 PCR                             153     153        0.58     8
  Broberg               2005   Sweden       Caucasians   Bladder cancer         PB                 PCR                             61      154        0.14     9
  Karagas               2005   USA          Mixed        Bladder cancer         PB                 PCR                             354     541        0.15     10
  Caceres               2005   Chile        Mixed        Prostate cancer        PB                 PCR-RFLP                        100     129        0.11     10
  Garcia-Closas         2005   Spain        Caucasians   Bladder cancer         HB                 TaqMan assay                    1146    1147       0.22     11
  Nam                   2005   Canada       Mixed        Prostate cancer        PB                 PCR-RFLP                        996     1092       0.23     13
  Ouerhani              2006   Tunisia      Africans     Bladder cancer         PB                 PCR                             62      79         0.44     3
  Kogevinas             2006   Spain        Caucasians   Bladder cancer         HB                 TaqMan assay                    99      91         0.19     7
  Silig                 2006   Turkey       Caucasians   Prostate cancer        HB                 PCR                             152     169        0.18     7
  Mittal                2006   India        Indians      Prostate cancer        HB                 PCR                             54      105        0.29     7
  Yang                  2006   China        Asians       Prostate cancer        HB                 PCR                             163     202        0.47     9
  Nock                  2006   USA          Caucasians   Prostate cancer        HB                 PCR                             438     479        0.17     9
  Shao                  2006   China        Asians       Bladder cancer         PB                 PCR                             405     389        0.50     10
  Agalliu               2006   USA          Africans     Prostate cancer        PB                 PCR                             31      15         0.47     11
  McGrath               2006   USA          Mixed        Bladder cancer         PB                 PCR                             191     924        0.16     13
  Agalliu               2006   USA          Caucasians   Prostate cancer        PB                 PCR                             558     522        0.17     14
  Lindstrom             2006   Sweden       Caucasians   Prostate cancer        PB                 PCR                             1299    728        0.15     14
  Cengiz                2007   Turkey       Caucasians   Bladder cancer         HB                 PCR                             51      53         0.21     5
  Cunningham            2007   USA          Mixed        Prostate cancer        PB                 PCR                             499     493        0.43     8
  Wiesenbutter          2007   Germany      Caucasians   Renal cell caicinoma   HB                 PCR                             98      324        0.18     8
  Mallick               2007   Guadeloupe   Mixed        Prostate cancer        HB                 PCR                             134     134        0.37     8
  Kellen                2007   Belgium      Caucasians   Bladder cancer         PB                 PCR                             194     380        0.16     9
  Zhao                  2007   USA          Mixed        Bladder cancer         PB                 PCR                             623     634        0.18     12
  Moore                 2007   Europe       Caucasians   Renal cell caicinoma   HB                 PCR                             861     1199       0.17     12
  Lima                  2008   Brasil       Caucasians   Prostate cancer        HB                 PCR                             125     100        0.22     6
  Covolo                2008   Italy        Caucasians   Bladder cancer         PB                 PCR                             197     211        0.16     7
  Davydova              2008   Russia       Caucasians   Prostate cancer        PB                 PCR                             61      100        0.22     7
  Song                  2008   China        Asians       Bladder cancer         HB                 PCR                             108     112        0.52     7
  Grando                2008   Brasil       Mixed        Bladder cancer         PB                 PCR                             100     100        0.37     8
  Karami                2008   Europe       Caucasians   Renal cell caicinoma   HB                 PCR                             628     913        0.18     9
  Yuan                  2008   USA          Caucasians   Bladder cancer         PB                 PCR                             658     680        0.18     12
  Altayli               2009   Turkey       Caucasians   Bladder cancer         HB                 PCR                             135     128        0.07     7
  Sivonova              2009   Slovakia     Caucasians   Prostate cancer        PB                 PCR                             129     228        0.20     8
  Song                  2009   China        Asians       Bladder cancer         HB                 PCR                             208     212        0.50     8
  Lavender              2009   USA          Africans     Prostate cancer        PB                 TaqMan assay                    189     584        0.17     10
  Souiden               2010   Tunisia      Caucasians   Prostate cancer        HB                 PCR                             110     122        0.15     6
  Coric                 2010   Serbia       Caucasians   Renal cell caicinoma   HB                 PCR                             76      182        0.29     8
  De Martino            2010   Austria      Caucasians   Renal cell caicinoma   HB                 PCR                             147     112        0.21     8
  Steinbrecher          2010   Germany      Caucasians   Prostate cancer        PB                 RT-PCR                          248     492        0.16     12
  Cantor                2010   Spain        Caucasians   Bladder cancer         HB                 TaqMan assay                    678     710        0.23     12
  Moore                 2010   USA          Caucasians   Bladder cancer         PB                 Melt curve/copy number assays   1004    1179       0.20     14
  Rouissi               2011   Tunisia      Africans     Bladder cancer         PB                 PCR                             125     125        0.30     4
  Kwon                  2011   Korea        Asians       Prostate cancer        PB                 PCR                             166     327        0.50     6
  Thakur                2011   India        Indians      Prostate cancer        PB                 PCR                             150     172        0.13     6
  Kumar                 2011   India        Caucasians   Prostate cancer        HB                 PCR                             57      46         0.48     6
  Rodrigues             2011   Brasil       Caucasians   Prostate cancer        PB                 PCR                             154     154        0.26     7
  Salinas-Sanchez       2011   Spain        Caucasians   Bladder cancer         HB                 PCR                             190     163        0.15     7
  Ashtiani              2011   Iran         Caucasians   Prostate cancer        HB                 PCR                             110     100        0.47     7
  Safarinejad           2011   Iran         Caucasians   Prostate cancer        PB                 PCR                             168     336        0.21     8
  Safarinejad           2011   Iran         Caucasians   Bladder cancer         PB                 PCR                             332     166        0.21     9
  Norskov               2011   Denmark      Caucasians   Prostate cancer        PB                 RT-PCR                          128     4409       0.15     10
  Koutros               2011   USA          Caucasians   Bladder cancer         PB                 Melt curve/copy number assays   215     289        0.20     13
  Goerlitz              2011   Egypt        Caucasians   Bladder cancer         PB                 TaqMan assay                    617     620        0.25     13
  Henriquez-Hernandez   2012   Span         Caucasians   Bladder cancer         HB                 PCR                             90      81         0.49     4
  Ovsiannikov           2012   Germany      Caucasians   Bladder cancer         HB                 PCR                             196     235        0.20     4
  Salinas sanchez       2012   Spain        Caucasians   Renal cell caicinoma   HB                 PCR                             132     163        0.15     6
  Hemelrijck            2012   Germany      Caucasians   Prostate cancer        PB                 RT-PCR                          203     360        0.18     10
  Ahmad                 2012   India        Indians      Renal cell caicinoma   PB                 PCR                             196     250        0.42     11
  Catsburg              2012   USA          Mixed        Prostate cancer        PB                 TaqMan assay                    909     736        0.21     12
  Catsburg              2012   USA          Mixed        Prostate cancer        PB                 TaqMan assay                    491     736        0.21     12
  Lesseur               2012   USA          Caucasians   Bladder cancer         PB                 TaqMan assay                    557     810        0.16     14
  Sharma                2013   India        Indians      Bladder cancer         HB                 PCR                             50      50         0.36     4
  Choubey               2013   India        Indians      Prostate cancer        HB                 PCR                             51      134        0.13     5
  Kang                  2013   Korea        Asians       Bladder cancer         HB                 PCR                             110     220        0.58     7
  Berber                2013   Turkey       Caucasians   Bladder cancer         HB                 PCR                             114     114        0.14     7
  Matic                 2013   Serbia       Caucasians   Bladder cancer         HB                 PCR                             201     122        0.28     8
  Ceylan                2014   Turkey       Caucasians   Bladder cancer         PB                 PCR                             65      70         0.13     5
  Sa                    2014   Brazil       Caucasians   Prostate cancer        PB                 PCR                             196     208        0.23     7
  Reszka                2014   Poland       Caucasians   Bladder cancer         PB                 RT-PCR                          242     365        0.21     9
  Emeville              2014   Guadeloupe   Africans     Prostate cancer        PB                 RT-PCR                          629     622        0.31     13

###### 

Meta-analysis of the association between *GSTT1* null genotype and urinary system cancer risk

  ---------------------------------------------------------------------------------------------------------------------
  Variables              No. of studies   Sample size\   OR (95% CI)        *P* ^OR^    I^2^(%)   *P* ^heterogeneity^
                                          Case/control                                            
  ---------------------- ---------------- -------------- ------------------ ----------- --------- ---------------------
  All^a^                 117              26666/37210    1.13 (1.05-1.22)   **0.001**   65.0      **0.000**

  Type of cancer                                                                                  

  BC                     60               12887/15783    1.13 (1.03-1.24)   **0.012**   55.5      **0.000**

  PC                     46               11197/17321    1.14 (1.01-1.29)   **0.042**   72.6      **0.000**

  RCC                    11               2582/4106      1.10 (0.86-1.41)   0.436       66.5      **0.001**

  Ethnicity                                                                                       

  Caucasian              68               16458/23377    1.16 (1.05-1.27)   **0.002**   59.7      **0.000**

  Asian                  20               2922/3909      1.04 (0.90-1.19)   0.614       44.1      **0.019**

  African                5                1036/1425      0.80 (0.63-1.02)   0.066       19.5      0.290

  Indians                10               1043/1600      2.05 (1.70-2.48)   **0.000**   1.7       0.423

  Mixed                  14               5207/6899      0.95 (0.80-1.14)   0.596       71.0      **0.000**

  Source of control                                                                               

  HB                     49               9337/11133     1.10 (0.99-1.23)   0.070       53.3      **0.000**

  PB                     68               17329/26077    1.15 (1.04-1.27)   **0.005**   70.7      **0.000**

  Quality score                                                                                   

  ≤5 (low)               19               1803/2610      1.43 (1.13-1.79)   **0.002**   57.6      **0.001**

  5\<score≤10 (medium)   79               12956/21215    1.15 (1.04-1.26)   **0.005**   64.0      **0.000**

  \>10 (high)            19               11907/13385    0.96 (0.86-1.07)   0.438       61.7      **0.000**
  ---------------------------------------------------------------------------------------------------------------------

BC, Bladder cancer; RCC, Renal cell carcinoma; PC, Prostate cancer; HB, Hospital based; PB, Population based.

###### 

Meta-regression analysis of the main characteristics of the 117 studies

  Study characteristics   Coef.   Std. Err.   *t*     *P*         95%CI   
  ----------------------- ------- ----------- ------- ----------- ------- -------
  Type of cancer          -0.02   0.06        -0.38   0.703       -0.14   0.09
  Ethnicity               0.14    0.05        3.03    **0.003**   0.05    0.12
  Source of control       0.12    0.09        1.36    0.175       -0.05   0.29
  Quality score           0.28    0.09        -3.24   **0.002**   -0.45   -0.11
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